Human Immunology Biosciences, a clinical-stage biotech company, announced on Tuesday it emerged from stealth armed with $120 million. The company was developed by Monograph Capital and ARCH Venture Partners. It was started in 2021, per Crunchbase data. The San Francisco-based company is throwing its hat into the ring to tackle autoimmune and inflammatory diseases, a broad category of disease for which current treatments don't fix in full. Most drugs targeted at autoimmune and inflammatory diseases weaken the immune system, which makes patients more at risk of developing infection. Human Immunology Biosciences is targeting cells like plasma and mast cells that make up the immune system. The startup currently has two drug candidates in its arsenal. One of them, felzartamab, will target plasma cells that are considered the likely drivers of these diseases. It's the problem most drugs face, and that issue has propelled the targeted therapy movement in precision medicine we've seen in...
learn more
